Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 12 best multibagger stocks to buy heading into 2026. Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price target. The analyst attributed the bullish stance to positive data in the first quarter of 2026 from second-line biliary tract cancer studies. Newman sees tovecimig as ...